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Abstract
Background: Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy in the United States. Unfortunately, a
validated protein biomarker-screening test to detect early stage disease from peripheral blood has not yet been developed.
The present investigation assesses the ability to identify tumor relevant proteins from ovarian cancer proximal fluids,
including tissue interstitial fluid (TIF) and corresponding ascites, from patients with papillary serous EOC and translates these
findings to targeted blood-based immunoassays.
Methodology/Principal Findings: Paired TIF and ascites collected from four papillary serous EOC patients at the time of
surgery underwent immunodepletion, resolution by 1D gel electrophoresis and in-gel digestion for analysis by liquid
chromatography-tandem mass spectrometry, which resulted in an aggregate identification of 569 and 171 proteins from TIF
and ascites, respectively. Of these, peroxiredoxin I (PRDX1) was selected for validation in serum by ELISA and demonstrated
to be present and significantly elevated (p = 0.0188) in 20 EOC patients with a mean level of 26.0 ng/mL (69.27 SEM) as
compared to 4.19 ng/mL (62.58 SEM) from 16 patients with normal/benign ovarian pathology.
Conclusions/Significance: We have utilized a workflow for harvesting EOC-relevant proximal biofluids, including TIF and
ascites, for proteomic analysis. Among the differentially abundant proteins identified from these proximal fluids, PRDX1 was
demonstrated to be present in serum and shown by ELISA to be elevated by nearly 6-fold in papillary serous EOC patients
relative to normal/benign patients. Our findings demonstrate the facile ability to discover potential EOC-relevant proteins in
proximal fluids and confirm their presence in peripheral blood serum. In addition, our finding of elevated levels of PRDX1 in
the serum of EOC patients versus normal/benign patients warrants further evaluation as a tumor specific biomarker for EOC.
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Introduction
Approximately 22,220 women are diagnosed annually with
epithelial ovarian cancer (EOC) and over 13,000 succumb to this
disease [1]. Women with EOC have a 5-year survival rate of 18–
34%, where the poor prognosis is primarily due to the fact that the
majority of patients present with advanced stage disease [2].
Detection of early stage disease with an optimal screening test
would have a positive impact on overall survival; however, there
are no available biomarkers that are sufficiently sensitive or
specific for deployment of a suitable test to be of utility for
screening the general population. Mucin 16, also known as cancer
antigen (CA)-125, was discovered by antibody production of
tumor xenografts [3] and is readily detected in serum. An FDA-
approved CA-125 immunoassay is currently in use to monitor
disease response to chemotherapeutic treatment and recurrence;
however, measurement of CA-125 is ineffective for screening (an
off-label use) for EOC in the general population [4]. While
immunodetection of tumor-associated antigens has contributed to
the knowledge of the natural history of the disease, their measures
have yet to consistently identify early stage EOC.
High throughput gene expression analysis of normal ovarian
tissue compared to EOC has revealed unique gene signatures
expressed in EOC. Although these signatures have provided
further insight into the molecular biology of EOC, gene expression
does not consistently correlate with protein abundance [5],
particularly in peripheral blood, which represents the most
clinically relevant sample source for routine assay development
and measurement [6]. While proteomic profiling of serum
represents an attractive approach for biomarker discovery, this
strategy is analytically challenging due to the high dynamic range
of protein concentration in this sample, which impedes discovery
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of lower abundance, tumor-related proteins. Arising from the
inherent analytical challenges related to serum proteomics,
proximal fluids have gained increasing attention for conducting
candidate protein biomarker discovery [7]. In the case of EOC,
ascites represents an attractive sample source for candidate
discovery as it bathes non-adherent cancer cells and adjacent
mesothelial cells and contains abundant information including
growth, survival and metastasis signaling factors [8]. While ascites
is an important medium for conducting protein biomarker
discovery investigations, much like serum, it also contains proteins
present across a high dynamic range of concentration requiring
various fractionation techniques to in order to identify lower
abundant proteins [9].
Tissue interstitial fluid (TIF) is another sample that has gained
increasing attention as a substrate from which candidate protein
biomarker discovery from tumor tissue can be conducted. Tissue
interstitial fluid is a protein rich sample source that is hypothesized
to contain secreted, shed and/or effluxed proteins from the tumor
and neighboring stroma. Celis et al. were the first to investigate
proteins from breast cancer and normal TIF [10], where it was
demonstrated that proteins identified by MS-based proteomics
could be externally validated in a tissue microarray containing
over 70 breast carcinoma tissue samples [11]. In a more recent
investigation, an MS-based proteomics workflow for identifying
differentially abundant proteins in renal cell carcinoma (RCC)
demonstrated elevated levels of enolase 2 (ENO2) and thrombos-
pondin-1 (TSP1) in tumor TIF. These were also verified as present
and at elevated abundance in RCC patient serum samples as
compared to control serum [12]. This investigation demonstrated
that proteins discovered in TIF possess a high propensity for
translation to serum-based assays.
In the current study, we utilized an MS-based proteomics
workflow to identify tumor specific proteins from TIF and ascites
from EOC patients. Among the differentially abundant proteins
identified from these proximal fluids, peroxiredoxin 1 (PRDX1)
was demonstrated to be present in serum and shown by ELISA to
be elevated by nearly 6-fold in papillary serous EOC patients
relative to normal/benign patients. Our study adds further support
to the hypothesis that TIF represents an attractive proximal
biofluid for conducting candidate biomarker discovery for the
eventual early detection of EOC.
Results
The protein content recovered from TIF and ascites was
visualized by resolution on a 1D-PAGE gel (Figure 1). A significant
amount of human serum albumin (HSA) was present in both
samples, although at lower levels in TIF than ascites. This greater
level of HSA in ascites is significant as it effectively increases the
overall dynamic range of protein concentration between the
highest (e.g. HSA) and lowest abundant proteins in this sample
type. A greater representation of the proteome is apparent in the
TIF sample due to the lower overall contribution of HSA to the
total protein content. Given the different contribution of HSA in
these two samples, our investigation utilized an affinity-based
immunodepletion protocol to remove the classical highly abun-
dant serum proteins present in each sample. This methodology
resulted in an efficient removal of a number of highly abundant
proteins as shown for a TIF sample (Figure 1), allowing for a more
complete comparison of the proteomic content of ascites and TIF
following LC-MS/MS analysis.
Paired ascites and TIF were harvested from four patients
(Table 1), immunodepleted and equivalent protein amounts of
each resolved by 1D-PAGE. Each gel lane was cut into five
equivalent slices, in-gel digested and the peptide digests analyzed
by LC-MS/MS in duplicate, resulting in 10,274 proteins identified
across all samples, including those identified by a single peptide.
We chose to impose an exclusion criterion such that only those
proteins represented by two spectral counts or more across all four
patient samples from either TIF or ascites were retained for the
comparative proteomic data analysis, which resulted in a data set
comprised of 569 and 171 proteins identified in all four TIF and
ascites patient samples, respectively (Table S1; the raw LC-MS/
MS data files are available for download from the Tranche Data
Repository at https://proteomecommons.org/tranche/). Ingenu-
ity Pathway Analysis annotation of the cellular localization of
proteins identified revealed a large enrichment in cytoplasmic- and
nuclear-derived proteins in TIF relative to ascites (Figure 2). Not
surprisingly, a high proportion of extracellular proteins were
present in ascites as compared with TIF. Extracellular proteins
dominated the common proteins identified, with the vast majority
derived from ascites. Subcellular proteins generally originated
from TIF; these proteins were in higher concentration in TIF with
diminished levels in ascites. This contrasting difference in the
origin of cellular localization suggests that TIF contains proteins
highly reflective of the cellular composition of the tissue
microenvironment.
Among those proteins identified, peroxiredoxin 1 (PRDX1) was
identified in greater abundance (an average of 13-fold greater
spectral count) in TIF samples as compared to ascites. We
confirmed the presence and differential abundance of PRDX1 in
both biospecimens by western blot (Figure 3). While PDRX1 is
routinely identified and studied in tissue, we sought to determine if
the abundance of PRDX1 was elevated in serum from a naı¨ve
cohort (e.g. not part of our original discovery set) of 20 patients
with stage II or higher EOC (Table 2) as compared to patients
with a benign ovarian pathology (Table 3). The mean level of
PRDX1 from these 20 EOC patients was determined to be
26.0 ng/mL (69.27 SEM) and 4.19 ng/mL (62.58 SEM) from
the 16 control/benign ovarian populations as measured using a
commercially available PDRX1 ELISA. This approximate 6-fold
greater abundance of PDRX1 in serum of EOC patients was
found to be statistically significant (Figure 4, p = 0.0188).
Discussion
Presentation with abdominal fullness, early satiety, a pelvic mass
and ascites is typical for women with EOC, unfortunately
however, these symptoms often present only when the disease is
advanced in stage. A screening test to detect early stage ovarian
cancer, when the 5-year survival is nearly 70–90% [13], has yet to
be developed. The low incidence of early stage EOC precludes
extensive study of disease pathogenesis, thus most research occurs
in late stage disease. We identified women with advanced EOC
and collected paired ascites and TIF from ovarian cancer tumors
from each patient for proteomic analysis. Ascites and TIF were
immunodepleted of highly abundant proteins prior to LC-MS/MS
analysis. Our data revealed that ascites and TIF harbor very
different protein profiles. Ascites possesses proteomic characteris-
tics similar to that of serum, being composed largely of proteins
derived from the extracellular compartment. Conversely, TIF is
comprised of proteins more representative of a tissue microenvi-
ronment, with many derived from various compartments from
cells.
In our analysis, 569 proteins were identified in common
between all patient TIF samples, compared to 171 proteins
commonly identified in corresponding ascites fluid. Among these,
PRDX1 was identified in greater abundance in TIF samples as
Ovarian Cancer Proximal Fluid Proteomics
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compared to ascites. TIF is hypothesized to contain a higher
relative concentration of proteins derived through passive/
enzymatic shedding, secretion, efflux and apoptosis. In a similar
fashion, these same processes likely result in ‘‘leakage’’ of some or
all of these same proteins into the vasculature and peripheral
circulation. The observed greater level of PRDX1 in TIF relative
to ascites is not unexpected for manifold biologically- and
analytically-related reasons. From a biological standpoint, TIF is
largely derived from the tumor microenvironment and hence likely
to contain higher relative concentrations of tumor/stroma-derived
proteins as compared to other peripheral body fluids, such as
ascites and serum. The consequence of this difference in dynamic
range of protein concentration between these body fluids
effectively lowers the dynamic range of protein concentration in
ascites and/or serum as compared to TIF. For these reasons,
inclusion of proximal fluids such as TIF in proteomic-based
biomarker discovery investigations represents a novel strategy for
harvesting shed and secreted proteins proximal to the tumor tissue
microenvironment whose presence is likely to be reflected in serum
from the same patients.
PRDX1 is a ubiquitous tissue-derived protein with known
function as an antioxidant. PRDX1 primarily protects cells from
DNA damage and potential mutagenesis by forming alcohols
following enzymatic reaction with reactive oxygen species (ROS),
such as hydrogen peroxide and hydroxyl radicals [14]. PRDX1 is
of particular interest due to its known elevated level of gene
expression in numerous cancers [15,16]. PRDX1 presence in
carcinomas is associated with inhibition of apoptosis, equating to
increased tumor survival [16,17,18]. While there is limited data
with respect to PRDX1 and its effects on EOC pathogenesis and
clinical outcomes, Chung et al. have proposed that PRDX1
expression in EOC is a prognostic indicator of decreased survival
[19]. In addition, several other peroxiredoxin family members
(PRDX2-6) are thought to be linked to ovarian carcinogenesis,
where these have been reported to be elevated in borderline
ovarian tumors compared to benign ovarian lesions [20]. Maxwell
et al. recently conducted a large scale proteomic analysis of laser
microdissected endometrial cancer tissue and noted that even
stage I endometrial cancers had elevated levels of proteins involved
in oxidative stress and inflammation compared to normal
endometrium. PRDX1 was among the oxidative stress proteins
that was validated to be significantly elevated in stage I
endometrial cancer tissue [21]. In the present study, the presence
of PRDX1 in TIF and ascites from ovarian cancer patients was
verified by western blot to be elevated in abundance in TIF as
compared to ascites. Based on the hypothesis that a subset of TIF
Figure 1. 1D-PAGE of TIF and Ascites. (A) Representative ascites and TIF samples illustrating the presence of abundant protein species in both
samples as well as the complexity of the harvested TIF sample. (B) A representative TIF sample before and after immunodepletion with the Agilent
MARS Hu-14 immunoaffinity column.
doi:10.1371/journal.pone.0025056.g001
Table 1. Clinicopathological features of ovarian cancer
patients in the discovery set.
Patient Age Race Histology Stage
Neoadjuvant
Chemotherapy
1 49 Caucasian Papillary Serous IV None
2 39 Caucasian Papillary Serous IV None
3 67 Caucasian Papillary Serous IIC None
4 61 Caucasian Papillary Serous IIIC None
doi:10.1371/journal.pone.0025056.t001
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proteins represent shed/secreted proteins from the microenviron-
ment and hence may be exchangeable, and hence detectable,
within peripheral blood, we attempted to determine the levels of
PRDX1 in blood serum using a highly validated, commercially
available ELISA. These results demonstrated that patients with
advanced EOC had a 6-fold elevated level of PRDX1 in their
serum compared to patients with normal/benign ovaries
(p = 0.0188).
Figure 3. Cytoplasmic-derived peroxiredoxin 1 (PRDX1) is
confirmed in TIF and Ascites. Peroxiredoxin 1 verification via
western blot analysis in ascites (A) and TIF (B) recapitulates the results
obtained by the spectral count (SC) values measured from the liquid
chromatography-tandem mass spectrometry analysis of these samples.
doi:10.1371/journal.pone.0025056.g003
Figure 2. Gene ontology analysis for the origin of protein localization. Tissue interstitial fluid and ascites proteins which were identified by two
or more spectral counts in each biofluid, respectfully, were analyzed for cellular compartmentalization with Ingenuity Pathway Analysis (IPA). Nearly 85%
of TIF proteins originated in cytoplasm and/or nucleus. Ascites had a serum-like protein profile with 66% of proteins being extracellular in origin.
doi:10.1371/journal.pone.0025056.g002
Table 2. Clinicopathological features of epithelial ovarian
cancer patients in the validation set.
Patient Age Race Histology Stage Medical Comorbidities
1 74 Caucasian Papillary Serous IIIC
2 85 Caucasian Papillary Serous IIIC
3 69 Caucasian Papillary Serous IIIC Neoadjuvant
chemotherapy
4 70 Caucasian Papillary Serous IIIC
5 86 Caucasian Papillary Serous IIIC
6 48 Caucasian Papillary Serous IIIC
7 66 Caucasian Papillary Serous IIIC
8 64 Caucasian Papillary Serous IIIC
9 80 Caucasian Papillary Serous IIIC
10 70 Caucasian Papillary Serous IIIC
11 57 Caucasian Papillary Serous IIIC
12 68 Caucasian Papillary Serous IIIC Suboptimally debulked
13 48 Caucasian Papillary Serous IV
14 71 Caucasian Papillary Serous IIIC
15 77 Caucasian Papillary Serous IIIC Focal clear cell
differentiation
16 54 Caucasian Papillary Serous IIIC
17 60 Caucasian Papillary Serous IIIC
18 75 Caucasian Papillary Serous IIIC
19 84 Caucasian Papillary Serous IIIC Suboptimally debulked
20 48 Caucasian Papillary Serous IIIC
doi:10.1371/journal.pone.0025056.t002
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Although PRDX1 has not been reported previously to be
present in serum, based on the hypothesis that some (if not all) TIF
proteins are exchangeable with peripheral circulation, we utilized
a targeted ELISA-based approach to first verify this hypothesis
and secondarily to ask the question whether this protein is
differentially abundant in serum from patients with EOC as
compared to individuals with benign pathologies of the ovary. We
limited this external validation of PRDX1 to serum because
elevated levels of PRDX1 have already been demonstrated in
ovarian cancer tissue by western blot and immunohistochemistry
[19]. Ideally, panels of selected biomarkers are likely needed in
order to develop a validated screening test for early EOC detection
[22], our sole focus was to demonstrate the feasibility of translating
MS-based proteomic discoveries from TIF into targeted serum-
based assays, in this case PRDX1. We acknowledge that we
cannot conclude that PRDX1 is sufficiently sensitive and specific
to be considered as a screening biomarker for EOC based on our
limited validation sample cohort, however, that it is detectable and
elevated in ovarian cancer patient serum compared matched
benign controls provides further supporting evidence to the
hypothesis that protein candidates discovered in TIF are likely
to be present in peripheral circulation.
Materials and Methods
Patient Selection
Research was conducted under the University of Pittsburgh
Institutional Review Board approved protocol #IRB0406147. All
samples were obtained after review of written informed consent
and were de-identified upon collection and analyzed anonymous-
ly. Intra-operative collection of tumor, ascites and serum were
from patients with suspected ovarian cancer at the time of their
initial surgery and occurred within 30 min of surgical removal. All
patients were chemotherapy and radiation therapy naı¨ve. Patients
with advanced EOC (stage IIC or greater) and pathology-proven
papillary serous ovarian carcinoma subtype were selected for
sample processing and analysis. Serum used for validation of
PRDX1 was derived from an internal database of de-identified
patients classified as having EOC or benign ovarian pathology.
Clinicopathological details of these patients were limited to their
gynecologic history.
Sample Processing
For the processing of TIF, approximately 0.25–0.50 gram wet-
weight of tissue obtained at surgery was immediately washed twice
Table 3. Clinicopathological features of patients with benign ovarian pathology in the validation set.
Patient Age Race Ovarian Pathology Medical Comorbidities
1 42 Caucasian Normal
2 38 Caucasian Normal T1c N0 MO Infiltrating Ductal Carcinoma
3 48 Caucasian Normal Family History of Breast and Ovarian Cancer
4 43 Caucasian Mucinous Cystadenofibroma
5 37 Caucasian Endometriosis Family History of Ovarian Cancer
6 72 Caucasian Normal Stage IA Grade3 Endometrial Cancer
7 69 Caucasian Cystadenofibroma
8 47 Caucasian Normal Complex Atypical Hyperplasia
9 37 Caucasian R Mucinous Adenoma/L Endometrioma
10 35 Caucasian Normal T2 N0 MO Infiltrating Ductal Carcinoma/Brca 1 Mutation
11 77 Caucasian Normal
12 58 Caucasian Fibrothecoma
13 70 Caucasian Bilateral Serous Cystadenofibroma
14 42 Caucasian Normal
15 52 Caucasian Fibrothecoma
16 59 Caucasian Fibroma
doi:10.1371/journal.pone.0025056.t003
Figure 4. Peroxiredoxin 1 is elevated in serum from ovarian
cancer patients. Serum from 20 patients diagnosed with Stage IIC or
higher ovarian cancer (cases) and serum from 20 patients with benign
ovarian pathology (controls) was evaluated for PDRX1 presence and
quantity by ELISA. There was a statistically significant difference
between the mean PDRX1 levels (p = 0.0188) in the two groups.
doi:10.1371/journal.pone.0025056.g004
Ovarian Cancer Proximal Fluid Proteomics
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25056
for 5 min with 5 mL of phosphate buffered saline (PBS). The
tissues were then incubated in 1 mL of PBS for 1 h at 37uC.
Following incubation, tissue was removed and the TIF superna-
tant was clarified of cellular debris by centrifugation at 10006g for
2 min and stored at 280uC. Ascites samples were aliquotted into
microcentrifuge tubes, clarified at 10006g for 2 min and stored at
280uC. Total protein in the TIF and ascites samples was
quantified by the bicinchoninic (BCA) assay (Pierce, Rockville,
IL). Samples were concentrated using Microcon-3 centrifugal filter
devices (Millipore, Billerica, MA) according to the manufacturer’s
instructions and subjected to immunodepletion of the 14 most
abundant serum proteins using the Multiple Affinity Removal
System (Hu-14, Agilent Technologies, Inc., Santa Clara, CA)
according to the manufacturer’s protocol, with the substitution of a
46 sample dilution buffer rather than the 16 buffer to prevent
potential sample loss due to extensive concentration of the TIF
and ascites. The depleted TIF and ascites samples were exchanged
into 25 mM ammonium bicarbonate and protein was quantified
by BCA assay. Corresponding blood samples were collected in
red-top vacutainer venous collection tubes (Becton, Dickson and
Company, Franklin Lakes, NJ), permitted to clot at room
temperature for 45 min, centrifuged at 22006 g for 10 min to
collect serum and aliquotted and stored at 280uC.
In-gel Digestion Protocol
Ten micrograms each of ascites or TIF were resolved by 1D-
PAGE and gel bands were visualized by Coomassie blue. Five gel
bands were excised evenly across all samples and destained in
25 mM ammonium bicarbonate, 50% ACN. Gel slices were
reduced with 10 mM DTT at 56uC for 1 h followed by alkylation
with 55 mM iodoacetamide for 45 min at ambient temperature in
the dark. Samples were digested with trypsin overnight and peptides
were extracted from gel bands with 70% ACN/5% formic acid. All
samples were lyophilized to dryness and resuspended in 0.1%
trifluoroacetic acid prior to analysis by liquid chromatography (LC)-
tandem mass spectrometry (MS/MS).
Mass Spectrometry and Bioinformatic Analyses
The peptide extracts from each sample gel band were analyzed
in duplicate on a Dionex Ultimate 3000 liquid chromatography
system (Dionex, Sunnyvale, CA) coupled online via electrospray
ionization to a linear ion trap (LTQ) MS (ThermoFisher Scientific,
San Jose, CA). Separations were performed using 75 mm
i.d.6360 mm o.d.620 cm long fused silica capillary columns
(Polymicro Technologies, Phoenix, AZ) slurry packed in house
with 5 mm, 300 A˚ pore size C-18 silica-bonded stationary phase
(Jupiter, Phenomenex, Torrance, CA). Following sample injection
onto a C-18 precolumn (Dionex), the column was washed for
3 min with mobile phase A (2% acetonitrile, 0.1% formic acid) at
a flow rate of 30 mL/min. Peptides were eluted using a linear
gradient of 0.33% mobile phase B (0.1% formic acid in
acetonitrile)/minute for 130 min, then to 95% B in an additional
15 min, all at a constant flow rate of 200 nL/min. Column
washing was performed at 95% B for 15 min for all analyses after
which the column was re-equilibrated in mobile phase A prior to
subsequent injections. The MS was operated in a data-dependent
MS/MS mode in which each full MS scan was followed by seven
MS/MS scans performed in the linear ion trap (LIT) where the
seven most abundant peptide molecular ions were selected for
collision-induced dissociation (CID) using a normalized collision
energy of 35%. Data were collected over a broad precursor ion
selection scan range (m/z 375–1800) and dynamic exclusion was
enabled to minimize redundant selection of peptides previously
selected for CID.
Tandem mass spectra were searched against the UniProt human
protein database (11/09 release) from the European Bioinformatics
Institute (http://www.ebi.ac.uk/integr8), using SEQUEST (Bio-
works 3.3.1, ThermoFisher Scientific). Search criteria were set as
follows: peptides were searched fully tryptic with up to two missed
cleavage sites, dynamic modifications of methionine oxidation
(15.9949 Da) and cysteine carboxyamidomethylation (57.0215 Da),
precursor mass tolerance of 1.4 Da and fragment ion tolerance of
0.5 Da. Peptides were considered legitimately identified if they met
specific charge state and proteolytic cleavage-dependent cross
correlation scores of 1.9 for [M+H]1+, 2.2 for [M+2H]2+ and 3.5
for [M+3H]3+, and a minimum delta correlation of 0.08. A false
peptide discovery rate of less than 2% was determined by searching
the primary tandem MS data using the same criteria against a decoy
database wherein the protein sequences are reversed [5]. Results
were further filtered using software developed in-house, and
differences in protein abundance between samples were derived
by summing the total CID events that resulted in a positively
identified peptide for a given protein accession across all samples
(spectral counting) [23].
Western Blot Analysis
Ten mg of total protein from each sample was resolved by 1D-
PAGE using 4–12% Bis-Tris or 7% Tris-acetate NuPAGE gels
(Invitrogen Carlsbad, CA) and transferred to Immobilon-PSQ
PVDF membranes (Millipore) using the Invitrogen Xcell II Blot
Module according the manufacturer’s protocol. Primary antibody
was rat monoclonal anti-human PRDX1 (Abcam, Cambridge,
MA) and secondary antibody was horseradish peroxidase-
conjugated donkey anti-rat (Abcam Cambridge, MA), pre-
absorbed with serum. Membranes were blocked with 0.5% dried
milk with TBS with 0.1% Tween-20 (TBST) as the diluent.
Primary antibody were applied at 1:1000 in TBST and
membranes were incubated overnight at 4uC. Membranes were
washed with TBST and incubated with secondary antibody
(1:75,000 dilution) for 1 h at ambient temperature. Membranes
were washed with TBST and incubated with Pico Super Signal
ECL (ThermoFisher) for 5 min prior to chemiluminescent
exposure.
Peroxiredoxin 1 ELISA
The levels of abundance of PRDX1 in patient sera were
measured using the peroxiredoxin 1 Human ELISA kit (BioVen-
dor, Candler, NC) according to the manufacturer’s instructions.
Serum samples from patients with ovarian cancer and benign
pathology were diluted 1:3 prior to measurement and were
assayed simultaneously and in duplicate. Serial dilutions of
PRDX1 standard were assayed in parallel with serum samples.
The optical density was plotted against standard PRDX1
concentrations to generate the standard curve according to the
manufacturer’s protocol. A non-parametric Wilcoxon rank-sum
test was used to determine the significance of the difference
between the median PDRX1 quantities in sera of patients with
benign ovarian pathology versus patients with advanced EOC.
The null hypothesis was that data in the two observation groups
are independent samples from identical continuous distributions
with equal medians against the alternative hypothesis, that the
groups do not have equal medians. Significance was accepted at a
two-tailed p value,0.05.
Supporting Information
Table S1 Proteins identified from four epithelial ovar-
ian cancer patient matched ascites and tissue interstitial
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fluid (TIF). The list of protein identifications (rows) represent the
summed spectral counts (values) from analyses of ascites and TIF,
each of which were resolved by denaturing gel electrophoresis
from which five gel bands were in gel digested and analyzed in
duplicate by liquid chromatography-tandem mass spectrometry.
(XLS)
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